Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,880
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Tumor-infiltrating lymphocytes for melanoma immunotherapy

Oliver Keppa Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon,
Peng Liua Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
,
Laurence Zitvogelc INSERM U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France;d Gustave Roussy, ClinicObiome, Villejuif, France
&
Guido Kroemera Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France;e Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon
Article: 2175506 | Published online: 07 Feb 2023

References

  • Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–3. doi:10.18632/oncotarget.2998.
  • Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022;19(7):431–439. doi:10.1038/s41571-022-00630-4.
  • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214. doi:10.1016/j.cell.2015.03.030.
  • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa1503093.
  • Rohaan MW, Borch TH, van den Berg JH, Met O, Kessels R, Geukes Foppen MH, Stoltenborg Granhoj J, Nuijen B, Nijenhuis C, Jedema I, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113–2125. doi:10.1056/NEJMoa2210233.
  • Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
  • Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7:250–261.
  • Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102(1):127–141. doi:10.1016/S0022-1759(87)80018-2.
  • Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792–802. doi:10.1016/S1470-2045(17)30251-6.
  • Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-22-1922.
  • Knochelmann HM, Rivera-Reyes AM, Wyatt MM, Smith AS, Chamness R, Dwyer CJ, Bobian M, Rangel Rivera GO, Horton JD, Lilly M, et al. Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021;10(1):1959101. doi:10.1080/2162402X.2021.1959101.
  • Lipp JJ, Wang L, Yang H, Yao F, Harrer N, Muller S, Berezowska S, Dorn P, Marti TM, Schmid RA, et al. Functional and molecular characterization of PD1(+) tumor-infiltrating lymphocytes from lung cancer patients. Oncoimmunology. 2022;11(1):2019466. doi:10.1080/2162402X.2021.2019466.
  • Weber EW, Maus MV, Mackall CL. The EMERGING landscape of immune cell therapies. Cell. 2020;181(1):46–62. doi:10.1016/j.cell.2020.03.001.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.